Private equity investor Apposite Capital has made an additional investment in cancer imaging software company Mirada Medical, bringing its total investment since 2019 to $20 million.
One of Mirada's software products in development is Simplicit90Y, which enables personalized dosimetry planning for TheraSphere, a radiation-based cancer treatment that uses microscopic radioactive glass microspheres.
Mirada's software is used in over 2,000 hospitals globally, Apposite said.
